Nisamox Injection
País: Itàlia
Idioma: anglès
Font: HMA (Heads of Medicines Agencies)
Fitxa tècnica
(SPC)
03-03-2013
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
amoxicillin trihydrate 14 %w/v, Potassium clavulanate 3.5 %w/v
Disponible des:
Norbrook Laboratories Limited
formulario farmacéutico:
Suspension for injection
Área terapéutica:
Cattle
Data d'autorització:
2011-08-17
Fitxa tècnica
Revised: September 2012
AN: 00536/2012
Page 1 of 9
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nisamox Suspension for Injection (Belgium & UK)
Nisamox Suspension for Injection (Portugal)
Nisamox 175 mg Suspension for Injection (Spain)
Nisinject Suspension for Injection (Italy)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml supplies:
ACTIVE SUBSTANCE:
Amoxicillin (as Amoxicillin trihydrate)
140 mg
Clavulanic acid (as Potassium clavulanate)
35 mg
EXCIPIENTS:
Butylated hydroxyanisole (E320) 0.08 mg
Butylated hydroxytoluene (E321) 0.08 mg
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Suspension for injection.
An off-white to cream oily suspension.
4.
CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In cattle:
Respiratory infections
Soft tissue infections (e.g. joint/navel ill, abscesses etc.)
In Dogs:
Respiratory tract infections, urinary tract infections, skin and soft tissue
infections (e.g. abscesses, pyoderma, anal sacculitis and gingivitis.).
Revised: September 2012
AN: 00536/2012
Page 2 of 9
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to penicillin or other
substances of the beta-lactam group.
Do not use in animals with serious dysfunction of kidneys accompanied by
anuria or oliguria.
Do not use in rabbits, guinea pigs, hamsters or gerbils.
The use of the product is contra-indicated where resistance to the
combination of penicillins or other substances of the beta-lactam group is
known to occur.
4.4 SPECIAL WARNINGS FOR
Llegiu el document complet
